Document Detail

Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?
MedLine Citation:
PMID:  19796554     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Oesophageal scintigraphy is an effective, non-invasive screening test to detect oesophageal dysmotility and reflux. Our objective was to assess the long term effect of lansoprazole therapy on gastroesophageal dysmotility in systemic sclerosis (SSc). METHODS: 24 SSc patients were randomised to receive either lansoprazole 30 mg or placebo for 12 months. Gastroesophageal motility was assessed by scintigraphy at baseline, after 6 months and after 12 months. Symptoms were evaluated by self-reported gastrointestinal questionnaire. RESULTS: Of 21 patients starting treatment, 17 (81%) completed the first 6 months and 13 (62%) completed the study. 3 patients from each group were withdrawn due to adverse events. As expected, lansoprazole appeared to decrease frequency of gastroesophageal symptoms in the first 6 months of treatment, but long term benefit was not evident. Scintigraphy showed worsening oesophageal dysmotility in SSc patients irrespective of lansoprazole treatment. In addition, early signs of dysmotility were found in asymptomatic patients. We found no correlation of scintigraphy findings with symptoms of gastroesophageal dysmotility. CONCLUSION: Although lansoprazole 30 mg daily appears to suppress SSc-related gastroesophageal symptoms in the short term, benefit was not sustained at 12 months, and there was no evidence that progression of gastroesophageal motility was prevented. Scintigraphy findings did not correlate with symptoms of dysphagia.
A Pakozdi; H Wilson; C M Black; C P Denton
Related Documents :
18080054 - Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous a...
21946704 - Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bon...
17168984 - Study of 24 cases with congenital esophageal atresia: what are the risk factors?
22492824 - Tonsillectomy has beneficial effects on remission and progression of iga nephropathy in...
18388344 - Importance of in-hospital initiation of therapies and therapeutic inertia in secondary ...
18570924 - The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the p...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  27     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2009 May-Jun
Date Detail:
Created Date:  2009-10-02     Completed Date:  2010-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  5-8     Citation Subset:  IM    
Royal Free and University College Medical School, Centre for Rheumatology and Connective Tissue Diseases, Department of Medicine, University College London Hampstead Campus, Hampstead, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
Anti-Ulcer Agents / therapeutic use*
Disease Progression
Esophagus / pathology,  physiopathology,  radionuclide imaging
Gastroesophageal Reflux / diagnosis,  drug therapy*,  physiopathology
Gastrointestinal Motility / drug effects,  physiology
Middle Aged
Prospective Studies
Proton Pumps / antagonists & inhibitors*
Scleroderma, Systemic / drug therapy*,  pathology,  physiopathology
Treatment Outcome
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Proton Pumps; 103577-45-3/lansoprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Health-related quality of life of school-age children with familial Mediterranean fever.
Next Document:  Evidence of a selective nociceptive impairment in systemic sclerosis.